EGFR and non-small cell lung carcinoma: Likewise, immune metabolic reprogramming mediated by CD73-adenosine signaling has also been shown critical in the context of NSCLC (non-small cell lung cancer) harboring EGFR mutations, the presence of which typically predicts unresponsiveness to immunotherapy and is generally used as a biomarker to exclude patients for ICIs.